QIAGEN announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).

Spectrum Solutions® announced the acquisitions of Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic laboratory, and Microarrays, Inc., a leader in customer array-based products that are used as biological research tools.

Illumina and Myriad Genetics said on Thursday that they have expanded their strategic partnership on homologous recombination deficiency (HRD) testing.